07/12/2018 17:07:13

Edison issues outlook on Atossa Genetics (ATOS)

LONDON, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics’s (ATOS) endoxifen programs are advancing in their respective breast health programs. The firm recently reported positive safety data from its Phase I study on topical endoxifen in men, and it completed enrolment for its Phase II endoxifen study in women with elevated mammographic breast density (MBD). It is also advancing an oral endoxifen formulation in women refractory to tamoxifen, and is applying its intraductal microcatheter (IDMC) with cancer drug fulvestrant. Our rNPV-derived equity valuation is $23.9m, or $3.66 per share.

Atossa had $13.0m net cash at 30 September 2018. We expect its funds on hand to last into early 2020 and that it will raise $10m in 2019. For modelling purposes, we assign these financings to long-term debt. Our rNPV valuation includes the prospect of the firm’s topical and oral endoxifen programs for women, its IDMC-delivered fulvestrant program and now its gynecomastia program as well. We now obtain a lower rNPV valuation of $10.9m (vs $24.4m, previously), largely due to a lower success probability (4% vs 5%, previously) for the MBD program. After including Q318 net cash ($13.0m), we obtain an equity valuation of $23.9m, or $3.66 per fully diluted (FD) share (which assumes full conversion of 3,517 outstanding Series B convertible preferred shares into 1.0m common shares).

Click here

to view the full report.

All reports published by Edison are available to download free of charge from its website

www.edisoninvestmentresearch.com

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Pooya Hemami, +1 646 653 7026

Maxim Jacobs, +1 646 653 7027

healthcare@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn        https://www.linkedin.com/company/edison-investment-research

Twitter           www.twitter.com/Edison_Inv_Res

YouTube       www.youtube.com/edisonitv

edison logo.png

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Apr
I:SP500
  Hejsa.   Lige lidt læsestof til påsken.   Langsigtet konjunktur:   Overraskende stigning i de le..
29
17 Apr
VELO
  Den eneste TA-ekspert var for mig alpehue, og nogle ganske få andre. Langt de fleste, som udtaler ..
27
15 Apr
VELO
Solen skinner++Envarsus viser vejen med endnu engang rigtig gode data. https://www.ncbi.nlm.nih.gov..
23
18 Apr
 
Jeg har modtaget flg. fra Delfin : "Nå, så er jeg blokeret på EI. Hvorfor ved jeg ikke. Jeg har ikke..
22
13 Apr
TEVA
TheNote: Stigendende priser: Hvis man kigge på Walmarts seneste regnskab kan man se at deres omsætni..
22
17 Apr
 
EI hvorfor har I slettet mit indlæg 414414 og hele debatten om hvad en moderater bør blande sig i ? ..
21
13 Apr
NOVO-B
TheNote. Jeg er imponeret over din seriøsitet som trådstarter - men dybt overrasket over din reaktio..
15
12 Apr
BEO SDB
Jeg tænker at EI med rette kunne hjælpe dig til en 2 ugers pause, det ville ihvertfald hjælpe os and..
13
17 Apr
TEVA
Den er også svær lige nu fordi mange korte og lange signaler krydser ind over hinanden lige nu. Men ..
11
15 Apr
VWS
Vestas i 600.. 😊 Det er en stor dag... Tillykke til de tålmodige og trofaste aktionærer.. Endelig ..
11

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
HQDA Acquires 51% of Palua Airline and Tourism Companies
2
Upper Street Marketing Inc. Announces Strategic Partnership in Canada
3
Bragar Eagel & Squire, P.C. is Investigating Lyft, Inc. (LYFT) on Behalf of Stockholders and Encourages LYFT Investors to Contact the Firm
4
American Indian College Fund Celebrates 30 Years of Service to Native Americans Pursuing Higher Education
5
Oak Valley Bancorp Reports 1st Quarter Results

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
19 April 2019 10:20:21
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190410.2 - EUROWEB7 - 2019-04-19 11:20:21 - 2019-04-19 10:20:21 - 1000 - Website: OKAY